A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis
- PMID: 25039426
- DOI: 10.1111/resp.12343
A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis
Abstract
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a degenerative disease characterized by fibrosis following failed epithelial repair. Mesenchymal stromal cells (MSC), a key component of the stem cell niche in bone marrow and possibly other organs including lung, have been shown to enhance epithelial repair and are effective in preclinical models of inflammation-induced pulmonary fibrosis, but may be profibrotic in some circumstances.
Methods: In this single centre, non-randomized, dose escalation phase 1b trial, patients with moderately severe IPF (diffusing capacity for carbon monoxide (DLCO ) ≥ 25% and forced vital capacity (FVC) ≥ 50%) received either 1 × 10(6) (n = 4) or 2 × 10(6) (n = 4) unrelated-donor, placenta-derived MSC/kg via a peripheral vein and were followed for 6 months with lung function (FVC and DLCO ), 6-min walk distance (6MWD) and computed tomography (CT) chest.
Results: Eight patients (4 female, aged 63.5 (57-75) years) with median (interquartile range) FVC 60 (52.5-74.5)% and DLCO 34.5 (29.5-40)% predicted were treated. Both dose schedules were well tolerated with only minor and transient acute adverse effects. MSC infusion was associated with a transient (1% (0-2%)) fall in SaO2 after 15 min, but no changes in haemodynamics. At 6 months FVC, DLCO , 6MWD and CT fibrosis score were unchanged compared with baseline. There was no evidence of worsening fibrosis.
Conclusions: Intravenous MSC administration is feasible and has a good short-term safety profile in patients with moderately severe IPF.
Keywords: cell therapy; idiopathic pulmonary fibrosis; infusion; mesenchymal stromal cells; short-term safety.
© 2014 Asian Pacific Society of Respirology.
Similar articles
-
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24. Chest. 2017. PMID: 27890713 Free PMC article. Clinical Trial.
-
Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis.Rev Mal Respir. 2011 Sep;28(7):e52-7. doi: 10.1016/j.rmr.2011.06.006. Epub 2011 Jul 30. Rev Mal Respir. 2011. PMID: 21943547 Clinical Trial.
-
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129. JAMA. 2018. PMID: 29800034 Free PMC article. Clinical Trial.
-
Pulmonary hypertension in chronic lung diseases.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Review.
-
Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.Am J Respir Crit Care Med. 2013 Jul 15;188(2):133-40. doi: 10.1164/rccm.201207-1204PP. Am J Respir Crit Care Med. 2013. PMID: 23306542 Review.
Cited by
-
Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic.Am J Stem Cells. 2024 Apr 25;13(2):37-58. doi: 10.62347/JAWM2040. eCollection 2024. Am J Stem Cells. 2024. PMID: 38765802 Free PMC article. Review.
-
In Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis.Cells. 2024 Jan 16;13(2):160. doi: 10.3390/cells13020160. Cells. 2024. PMID: 38247851 Free PMC article.
-
The Plastic Interplay between Lung Regeneration Phenomena and Fibrotic Evolution: Current Challenges and Novel Therapeutic Perspectives.Int J Mol Sci. 2023 Dec 31;25(1):547. doi: 10.3390/ijms25010547. Int J Mol Sci. 2023. PMID: 38203718 Free PMC article. Review.
-
Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms.Immune Netw. 2023 Dec 11;23(6):e45. doi: 10.4110/in.2023.23.e45. eCollection 2023 Dec. Immune Netw. 2023. PMID: 38188598 Free PMC article.
-
Emerging delivery approaches for targeted pulmonary fibrosis treatment.Adv Drug Deliv Rev. 2024 Jan;204:115147. doi: 10.1016/j.addr.2023.115147. Epub 2023 Dec 6. Adv Drug Deliv Rev. 2024. PMID: 38065244 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical